174691-84-0

Upstream product

• 406174-94-5 (1R,2S)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid 2,6-di-tert-butyl-4-methoxy-phenyl ester 
• 675872-23-8 (1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-nitro-1-(2-trityloxymethylphenyl)naphthalene 
• 675872-24-9 {2-[(1S,2R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-nitronaphthalen-1-yl]phenyl}methanol 
• 166591-12-4 1,2-dihydro-6,7-dimethoxy-3-nitronaphthalene 
• 132814-55-2 (((2-bromobenzyl)oxy)methanetriyl)tribenzene 
• 406499-03-4 (6aR,12bS)-(+)-10,11-dimethoxy-5,6,6a,7,8,12b-hexahydrobenzophenanthridine 
• 406174-96-7 N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-methoxymethyl-4-methyl-benzenesulfonamide 
• 406174-97-8 (6aR,12bS)-10,11-Dimethoxy-6-(toluene-4-sulfonyl)-5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine 
• 406174-93-4 6,7-dimethoxy-3,4-dihydro-naphthalene-2-carboxylic acid 2,6-di-tert-butyl-4-methoxy-phenyl ester 
• 406174-95-6 N-((1R,2R)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-4-methyl-benzenesulfonamide 
• 406174-92-3 (1R,2R)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid 
• 406174-91-2 (1R,2R)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylamine 

Downstream Products

• 137417-08-4 (+)-Dihydrexidine hydrochloride 

Relevant academic research and scientific papers

The first asymmetric synthesis of a dopamine D1 agonist, dihydrexidine, employing asymmetric conjugate addition technology

The first asymmetric synthesis of benzophenanthridine dopamine D1 full agonist, dihydrexidine, was accomplished employing three key processes, external chiral ligand-controlled conjugate addition of phenyllithium, Curtius conversion of a carboxylic group

Co-administration of dopamine-receptor binding compounds

Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D1 receptor agonist and a dopamine D2 receptor antagonist are also described. The D1 dopamine receptor agonist and the D2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

Improved asymmetric synthesis of dopamine D1 full agonist, dihydrexidine, employing chiral ligand-controlled asymmetric conjugate addition of aryllithium to a nitroalkene

Asymmetric conjugate addition of 2-trityloxymethylpheyllithium to a nitroalkene was mediated by a chiral ligand to give the key intermediate for dopamine D1 full agonist dihydrexidine 1. The shortcut of both Curtius rearrangement and Pictet-Spengler type

Dopaminergic benzo[a]phenanthridines: Resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist

Racemic trans-10,11-dihydroxy-5,6,6a,7,8,12b- hexahydrobenzo[a]phenanthridine (2, dihydrexidine) was shown previously to be the first bioavailable full efficacy agonist at the D1 dopamine receptor. In addition to its full D1 agonist